Background-Although rapid HIV tests increase the number of persons who are aware of their HIV status, they may fail to detect early HIV infection.
Background
The Centers for Disease Control and Prevention has encouraged expanded HIV testing 1 to identify the estimated 21% of persons living with HIV who remain undiagnosed. 2 Rapid HIV tests have been widely adopted as an essential component of HIV prevention programs because they are ideal tools to increase the number of persons who are aware of their HIV status. Rapid HIV tests offer several advantages because they are simple and easy to use; can be used in outreach, point-of-care, and nonclinical settings; return results faster than conventional tests (usually in ≤30 min); and minimize the extent to which clients fail to return for test results. 3 For these reasons, rapid HIV tests are commonly used in venues that reach persons at high risk for acquiring HIV.
Although rapid HIV tests increase the number of persons who are aware of their HIV status, the current Food and Drug Administration (FDA)-approved rapid tests may have limited sensitivity for the diagnosis of early HIV infection, 4, 5 resulting in missed opportunities for HIV prevention. Early HIV infection is the stage of infection prior to HIV seroconversion or Western blot positivity ( Fig. 1 ). 6 Many rapid tests seem to detect HIV only a few days before the Western blot. 4, 5 The earliest phase of early HIV infection is acute HIV infection (AHI) which represents the stage of infection in which HIV RNA and p24 antigen can be detected but HIV antibodies are not yet detectable by earlier generation immunoassays (IAs), such as third-generation IAs which detect IgM and IgG HIV antibodies using an antigen-antibodyantigen sandwich technique, second-generation IAs which detect IgG antibodies to HIV recombinant proteins, and first-generation IAs which detect IgG antibodies to viral lysate. 4, 6 Only more-sensitive IAs, such as fourth-generation IAs which detect p24 antigen in addition to IgM and IgG HIV antibodies using the third-generation technique, and nucleic acid amplification tests (NAAT) can detect persons with AHI. 7, 8 Because NAAT is difficult to perform in outreach settings, we evaluated the sensitivity of rapid tests, including fourthgeneration rapid tests, for early HIV infection compared with NAAT and third-and fourthgeneration IAs. We believe these results are vital to inform HIV screening practices in highrisk outreach settings.
Objectives
The aim of this study was to examine the sensitivity of rapid and fourth-generation tests to detect early HIV infection.
Study design

CDC AHI study
The CDC AHI study was an observational study to evaluate several strategies for detecting AHI in Los Angeles (LA), New York City (NYC) and Florida. From April 24, 2006 to March 28, 2008, all persons who consented for HIV testing, including NAAT, at 14 county sexually transmitted disease (STD) clinics and one gay community clinic in LA, three health department STD clinics in NYC, and approximately 80 public health clinics in four Florida counties participated in this study. The primary objective was to evaluate the yield of pooled NAAT after first-, second-, and third-generation HIV antibody screening. However, one secondary objective was to examine the sensitivity of rapid and fourth-generation tests to detect early HIV infection. The study design and methods have been previously described. 8
Testing protocol
Plasma specimens were collected from all consenting patients at the study sites. All persons were initially screened for HIV antibody; however, each project area used a different test for initial screening: Florida used a third-generation assay (Genetic Systems HIV 1/2 + O ® ) on serum specimens and in a few study sites, a second-generation rapid test on fingerstick specimens (Oraquick ® ), NYC used a second-generation rapid test (Oraquick Advance ® ) on oral fluid specimens, and LA used a first-generation assay (Vironostika HIV-1 Microelisa System ® ) on serum specimens. Specimens that were negative or indeterminate by serologic testing underwent NAAT (APTIMA ® HIV-1 RNA ® Qualitative assay) and viral load quantification (Siemens Versant ® HIV-1 RNA 3.0 assay).
To evaluate sensitivity for early HIV infection using NAAT as a gold standard, all NAATpositive specimens underwent third-generation testing with Genetic Systems 1/2 + O ® IA and rapid testing with Multispot HIV-1/HIV-2 ® . Initial and follow-up specimens that remained antibody (Ab)-negative by screening IAs from 55 persons with AHI were included in this panel of NAAT-positive specimens; therefore all specimens were collected during early HIV infection. A subset of plasma specimens with sufficient quantity was stored at −70 °C and later tested with four other FDA-approved rapid HIV tests (Clearview Complete ® , Unigold Recombigen ® , Clearview HIV 1/2 Statpak ® , and Oraquick Advance Rapid HIV-1/2 ® ) and underwent fourth-generation testing with Determine HIV-1 Antigen/ Antibody Rapid Test ® and Architect HIV Antigen/Antibody Combo ® , a lab-based immunoassay (Fig. 2 ). All rapid test devices were read by two trained laboratorians at each site and consensus was obtained regarding the test results. Characteristics of the lab-based assays and rapid test devices used in this evaluation are provided in Table 1 . Test performance characteristics with confidence intervals (e.g., sensitivity) were calculated using OpenEpi version 2.2.1 (Emory Rollins School of Public Health, Atlanta, Georgia).
To evaluate fourth-generation screening for AHI detection, an unlinked, anonymous, blinded panel of 40 AHI, 44 HIV Ab-positive, and 30 HIV-negative specimens was tested with Determine HIV-1 Antigen/Antibody Rapid Test ® and Architect HIV Antigen/Antibody Combo ® IA. The 40 AHI specimens were from persons with documented subsequent seroconversion and included initial and follow-up specimens from the same individual. Because these assays were not approved by the FDA at the time, this evaluation was conducted retrospectively and results were not reported to participants; however it was expected that the fourth-generation test results would not alter the interpretation of participants' HIV test results.
Results
Of 99,111 specimens screened from April 2006 to March 2008, 60 specimens were NAATpositive/Ab-negative by one of three different screening IAs and 2 were NAAT-positive/WBindeterminate. Of these 62 specimens, half had HIV viral loads >500,000 copies/mL (range: <75-6,334,400 copies/mL). Genetic Systems 1/2 + O ® correctly detected antibody in 34 of 62 specimens (55%; 95% confidence interval (CI): 42-67); Multispot detected antibody in 16 of 62 specimens (26%; 95% CI: .
Of the 62 specimens, 33 (53%) had sufficient quantity for further testing. Because testing was done sequentially, the amount of specimen available for testing was exhausted in a few instances. Fourth-generation testing with Architect was positive in 29 of 33 (88%) specimens; Determine identified antibody or antigen (Ag) in 25 of 33 (76%) specimens ( Table 2) Table 2 ).
Fourth-generation testing of the blinded specimen panel resulted in 0 false-positive and 10 false-negative results by Determine and 2 false-positive, 5 false-negative, and 2 error results by Architect. Therefore, the sensitivity of Determine compared with NAAT was 0.88 (95% CL: 0.79-0.94) and specificity was 1.00 (95% CL: 0.91-1.00). The sensitivity of Architect compared with NAAT was 0.94 (95% CL: 0.87-0.98) and specificity was 0.93 (95% CL: 0.79-0.99).
Discussion
Our findings suggest that, as expected, many FDA-approved rapid HIV tests failed to detect early HIV infection in half of the cases in whom antibody was present. Rapid test sensitivities for early HIV infection in our study ranged from 22-33% compared with 55-57% for the third-generation assay and 76-88% for the fourth-generation assays. Although the sensitivities of rapid HIV tests for established HIV infection are high, 9 rapid tests have varying ability to detect HIV infection during the early seroconversion period 4,5,10 and their ability to do so is substantially lower than third-and fourth-generation lab-based assays as well as rapid tests that also detect HIV antigens. Therefore, widespread use of rapid HIV testing, particularly among high-risk/high-incidence populations, may have insufficient public health benefits by failing to detect persons with early HIV infection and missing opportunities to interrupt onward HIV transmission. Persons with early HIV infection are more likely to transmit HIV infection than persons with established infection, 11 contributing significantly to overall HIV transmission. 12 Studies have shown that NAAT can detect a high number of persons with early HIV infection who screened false-negative by a rapid HIV test. 8, 13 Thus, programs that screen high-risk/high-incidence populations with rapid tests should consider supplemental testing with NAAT or other antigen-based tests.
Although NAAT is presently the gold standard for the diagnosis of AHI, its use is limited by cost, 14 the longer turnaround time of test results, and the need for venipuncture and a sophisticated laboratory. Fourth-generation combination assays that detect both HIV antibodies and p24 antigen may be a practical substitute for NAAT. 8 These more-sensitive assays are used worldwide, have a high sensitivity for HIV infection overall 15 and detected up to 88% of early HIV infection specimens in our study. Although fourth-generation testing will miss a few cases that may be detected by NAAT, frequent testing of persons who have recently participated in high risk activity should be encouraged to maximize HIV detection rates. 16 Even NAAT will miss cases of HIV particularly during the eclipse period when HIV RNA may be present in very small quantities but is undetectable. 6 and among a small number of persons who maintain viral suppression without antiretroviral therapy.
In outreach settings where rapid tests are traditionally used, the fourth-generation rapid test may be a good screening assay. In our evaluation, the fourth-generation rapid test was able to detect early HIV infection in 76% of specimens, at least twice as many as the other rapid tests and more than the third-generation lab-based assay. Furthermore, although the fourthgeneration rapid test had a lower sensitivity than the lab-based fourth-generation assay, its specificity was higher which is important when delivering positive HIV results to high-risk individuals at the point of care.
Our study had a few limitations. We conducted this evaluation on a small sample size; however specimens collected during early HIV infection are in general rare. We conduct testing on the initial sample submitted by the participant for HIV testing so specimens were often exhausted or of limited quantity after routine HIV testing for screening and confirmation was conducted. We did not conduct a real-time evaluation of the fourthgeneration tests because neither was FDA-approved at the time that the CDC AHI study was conducted. Therefore, specimens were frozen and stored for future testing. Freeze-thaw cycles were limited (≤2) but test results may have been affected by freezing and thawing.
These data support the need for FDA-approval of more sensitive antigen-based point-of-care screening tests for early HIV infection. Fourth-generation rapid tests are presently used worldwide and the approval of their use in the United States would allow for more effective screening of early HIV infection in hard-to-reach, high-risk populations to increase the number of persons who are aware of their HIV infection. Furthermore, point-of-care HIV RNA tests, which are currently being tested in clinical trials, may also be a useful tool for detection of early HIV infection in outreach settings. Specimen testing algorithm for early HIV infection. Patel Table 1 Summary of characteristics of lab-based assays and rapid testdevices for HIV detection. 
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